title: New and Emerging Treatments for Rosacea.
abstract: Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews new treatment options including ivermectin, brimonidine, the new foam formulation of azelaic acid, and oxymetazoline. The potential role in therapy, patient selection, and adverse effects of these agents are discussed.
authors.affiliation: Henry Ford Hospital, 6530 Farmington Road, West Bloomfield, Detroit, MI, 48322, USA. laurgold@umich.edu.
authors.forename: Lauren M
authors.initials: LM
authors.lastname: Gold
authors.affiliation: Dermatology Consulting Services, High Point, NC, USA.
authors.forename: Zoe Diana
authors.initials: ZD
authors.lastname: Draelos
mesh_terms: D000287:Administration, Topical; D000068438:Brimonidine Tartrate / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003879:Dermatologic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003998:Dicarboxylic Acids / Q000627:therapeutic use; D017277:Drug Approval / Q000706:statistics & numerical data*; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use; D008297:Male; D010109:Oxymetazoline / Q000627:therapeutic use; D017060:Patient Satisfaction / Q000706:statistics & numerical data; D012393:Rosacea / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D003879:Dermatologic Agents; D003998:Dicarboxylic Acids; D000068438:Brimonidine Tartrate; D007559:Ivermectin; D010109:Oxymetazoline; C010038:azelaic acid